Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Dallas, Texas

Phase 1 cancer trials in Dallas, TX

100 Phase 1 cancer studies are recruiting participants at sites in Dallas as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

Breast cancer studies recruiting in Dallas

Basic details from each study's public record (the 30 most recently updated of 100). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT06253871 · updated
  2. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT06638307 · updated
  3. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Baylor Scott & White Research Institute -Texas Oncology · UT Southwestern Medical Center
    Registry record
    NCT06827236 · updated
  4. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    UT Southwestern
    Registry record
    NCT06586957 · updated
  5. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT07029399 · updated
  6. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT05579366 · updated
  7. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Texas Oncology - DFW (Sammons CC)
    Registry record
    NCT07213791 · updated
  8. Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT07604571 · updated
  9. Study of XB010 in Subjects With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Baylor University Medical Center
    Registry record
    NCT06545331 · updated
  10. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Blue Earth Diagnostics
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT07432633 · updated
  11. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Texas Oncology, P.A.
    Registry record
    NCT06330064 · updated
  12. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Texas Oncology (Worth) - USOR
    Registry record
    NCT07100106 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in Dallas

  1. A Study of VET3-TGI in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    KaliVir Immunotherapeutics
    Study site
    Mary Crowley Cancer Research/Sarah Cannon Research Institute
    Registry record
    NCT06444815 · updated
  2. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Mary Crowley Cancer Research Center
    Registry record
    NCT04886804 · updated
  3. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study sites
    NEXT Dallas · START Dallas- Fort Worth
    Registry record
    NCT07080242 · updated
  4. SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT07857616 · updated
  5. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT05856981 · updated
  6. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Dallas Fort Worth
    Registry record
    NCT07542704 · updated
  7. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Crescent Biopharma, Inc.
    Registry record
    NCT07909031 · updated
  8. SW-682 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
    Study site
    Mary Crowley Research Center US Oncology
    Registry record
    NCT06251310 · updated
  9. A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    UT Southwestern Medical Center at Dallas
    Registry record
    NCT07140016 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in Dallas

  1. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study sites
    Mary Crowley Cancer Research · University of Texas Southwestern Medical Center
    Registry record
    NCT05519449 · updated
  2. A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT07570979 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Melanoma studies recruiting in Dallas

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0054)
    Registry record
    NCT02332668 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in Dallas

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04726241 · updated
  2. A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Debiopharm International SA
    Study site
    Baylor Scott & White Research Institute
    Registry record
    NCT05765812 · updated
  3. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Texas Southwestern
    Registry record
    NCT07101328 · updated
  4. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Texas Oncology - DFW (Sammons CC)
    Registry record
    NCT07226843 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Dallas

  1. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    UT Southwestern University Hospital Radiology Clinic
    Registry record
    NCT06710756 · updated
  2. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    Mary Crowley Cancer Research · University of Texas Southwestern
    Registry record
    NCT04657068 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call